What question did this study set out to answer?

To synthesize current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic findings, and clinical management of immune effector cell-mediated enterocolitis following CAR-T cell therapy.

August 16, 2026Alimentary Pharmacology & Therapeutics

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR ‐T Cell Therapy—Clinical Features, Pathophysiology and Management

View Full Paper

Ask AI

Bookmark

Authors

JDJohn DamianosMayo Clinic YLYi LinSouth China Agricultural University ZCZongming Eric ChenMayo Clinic

Discussion

Member takes

Implication

Literature review reveals severe gastrointestinal enterocolitis occurs in up to 6% of CAR-T recipients, highlighting the need for prompt multidisciplinary intervention.

Key Points

To synthesize current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic findings, and clinical management of immune effector cell-mediated enterocolitis following CAR-T cell therapy.
Conducted a comprehensive literature synthesis analyzing all published case series of immune effector cell-mediated enterocolitis following CAR-T therapy to date.
Immune effector cell-mediated enterocolitis develops in up to approximately 6% of patients, presenting most commonly after B-cell maturation antigen-targeted CAR-T therapy.
The condition manifests with severe diarrhea and malabsorption, carries a poor prognosis, and responds poorly to conventional therapies.
Effective clinical management centers on early multidisciplinary identification, supportive care, exclusion of infections, and step-up pharmacotherapy adapted from inflammatory bowel disease regimens.

Cite This Study

Damianos et al. (2026) studied this question.

synapsesocial.com/papers/6a8179abf2fb91fc834aceaa https://doi.org/10.1111/apt.70920

View Full Paper

Ask AI

Bookmark

Implication

Literature review reveals severe gastrointestinal enterocolitis occurs in up to 6% of CAR-T recipients, highlighting the need for prompt multidisciplinary intervention.

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR ‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Discussion

Member takes

Implication

Key Points

Cite This Study

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR ‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider